Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect

International Journal of Cancer

Volumn 121, Issue 11, 2007, Pages 2539-2546

  Jin, Guang Hui ^a,b   Ma, Ding Yuan ^a   Wu, Ning ^c   Marikar, Faiz M M T ^a   Jin, Shun Zi ^c   Jiang, Wei Wei ^a   Liu, Yan ^a   Hua, Zi Chun ^a  

^a NANJING UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c JILIN UNIVERSITY   (China)

Author keywords

Angiogenesis; Lewis lung carcinoma; Plasminogen kringle 5; Radiation therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RECOMBINANT PLASMINOGEN KRINGLE 5 DOMAIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IONIZING RADIATION; LEWIS CARCINOMA; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VASCULARIZATION; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MICE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; RADIATION, IONIZING; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35649022119     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22708     Document Type: Article

References (28)

1. Owen JB, Coia LR, Hanks GE. Recent patterns of growth in radiation therapy facilities in the United States: a patterns of care study report. Int J Radiat Oncol Biol Phys 1992;24:983-6.
2. Jin GH, Jin SZ, Liu Y, Xu RM, Yang JZ, Pan XN, Liu SZ. Therapeutic effect of gene-therapy in combination with local X-irradiation in a mouse malignant melanoma model. Biochem Biophys Res Commun 2005;330:975-81.
3. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst 1996;88:1193-203.
4. Stratford IJ. Concepts and developments in radiosensitization of mammalian cells. Int J Radiat Oncol Biol Phys 1992;22:529-32.
5. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003;63:8890-8.
6. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394:287-91.
7. Luo X, Andres ML, Timiryasova TM, Fodor I, Slater JM, Gridley DS. Radiation-enhanced endostatin gene expression and effects of combination treatment. Technol Cancer Res Treat 2005;4:193-202.
8. Fenton BM, Paoni SF, Ding I. Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res 2004;64:5712-19.
9. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275-88.
10. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003;9:1957-71.
11. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
12. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O'Reilly MS, Llinas M, Folkman J. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996;271:29461-7.
13. Gao G, Li Y, Gee S, Dudley A, Fant J, Crosson C, Ma JX. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the antiangiogenic activity of plasminogen kringle 5. J Biol Chem 2002;277: 9492-7.
14. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997;272:22924-8.
15. Lu H, Dhanabal M, Volk R, Waterman MJ, Ramchandran R, Knebelmann B, Segal M, Sukhatme VP. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem Biophys Res Commun 1999;258:668-73.
16. Ji WR, Barrientos LG, Llinas M, Gray H, Villarreal X, DeFord ME, Castellino FJ, Kramer RA, Trail PA. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun 1998;247: 414-19.
17. Davidson DJ, Haskell C, Majest S, Kherzai A, Egan DA, Walter KA, Schneider A, Gubbins EF, Solomon L, Chen Z, Lesniewski R, Henkin J. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res 2005;65:4663-72.
18. Zhu M, Cheng J, Hua ZC. Expression of kringle 5 domain of human plasminogen in Pichia pastoris. Prep Biochem Biotechnol 2003;33: 269-81.
19. Sun QM, Cao L, Fang L, Chen C, Dai J, Chen LL, Hua ZC. Expression, purification of human vasostatin 120-180 in Escherichia coli, and its anti-angiogenic characterization. Protein Expr Purif 2005; 39:288-95.
20. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:54-66.
21. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Baron AE, Zeng C, Johnson TK, Bunn PA Jr. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005;11:795-805.
22. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
23. Dings RP, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 2005;115:312-19.
24. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
25. Nasu S, Ang KK, Fan Z, Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001;51:474-7.
26. Lund EL, Hog A, Olsen MW, Hansen LT, Engelholm SA, Kristjansen PE. Differential regulation of VEGF, HIF1α and angiopoietin-1, -2 and -4 by hypoxia and ionizing radiation in human glioblastoma. Int J Cancer 2004;108:833-8.
27. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004;5:429-41.
28. Fang J, Yan L, Shing Y, Moses MA. HIF-1α-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 2001;61:5731-5.